106%+ returns, 97% win rate: A fresh list of AI-picked stock is out NOW
As of December 31, 2024, Alphatec's cash balance was approximately $139 million, reflecting an increase of $58 million from the third quarter of 2024. This includes $50 million in proceeds from the term loan expansion announced with the third quarter financial results. InvestingPro metrics show the company maintains strong liquidity with a current ratio of 2.32, indicating its liquid assets exceed short-term obligations. For detailed financial health analysis and additional insights, investors can access the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers. InvestingPro metrics show the company maintains strong liquidity with a current ratio of 2.32, indicating its liquid assets exceed short-term obligations. For detailed financial health analysis and additional insights, investors can access the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers.
As of December 31, 2024, Alphatec's cash balance was approximately $139 million, reflecting an increase of $58 million from the third quarter of 2024. This includes $50 million in proceeds from the term loan expansion announced with the third quarter financial results. InvestingPro metrics show the company maintains strong liquidity with a current ratio of 2.32, indicating its liquid assets exceed short-term obligations. For detailed financial health analysis and additional insights, investors can access the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers.
As of December 31, 2024, Alphatec's cash balance was approximately $139 million, reflecting an increase of $58 million from the third quarter of 2024. This includes $50 million in proceeds from the term loan expansion announced with the third quarter financial results.
Looking ahead, Alphatec anticipates a total revenue of $732 million for the full year of 2025, which would mark a growth of about 20% compared to 2024. This forecast includes surgical revenue of approximately $657 million and EOS revenue of around $75 million. The company also expects to achieve positive free cash flow, with adjusted EBITDA projected at approximately $75 million.
In addition to the financial results and outlook, the company announced the granting of 26,013 restricted stock units to 12 new employees as an inducement to employment, in accordance with Nasdaq Listing Rule 5635(c)(4).
Alphatec will report its complete fourth quarter and full-year 2024 financial results on February 26, 2025, after the market close, followed by a live webcast.
The preliminary revenue results are subject to adjustment upon the completion of the company's annual audit procedures. The company's performance is seen as an indicator of its dedication to revolutionizing spine surgery and achieving profitability.
This report is based on a press release statement from Alphatec Holdings (NASDAQ:ATEC), Inc. and does not include any speculative information or subjective assessments.
In other recent news, Alphatec Spine (ATEC) reported a robust third-quarter performance, with a 27% year-over-year revenue growth to $151 million, including a 30% increase in surgical revenue. The company also achieved a significant $7.4 million adjusted EBITDA, marking a turnaround from a previous loss. ATEC also announced future targets, including a revenue goal of approximately $605 million for 2024 and an adjusted EBITDA of $70 million for 2025, when the company aims to reach cash flow breakeven.
Meanwhile, Paragon 28, Inc. expanded its Board of Directors with the appointment of Dave Demski, an experienced leader in the medical technology sector. This strategic move is expected to enhance the company's governance and oversight.
Piper Sandler analysts highlighted several healthcare companies, including ATEC, in anticipation of an investor conference in San Francisco. The analysts remain optimistic about these companies' fiscal year outlooks and potential for profitability improvement. The analysts also noted potential upside for consensus numbers for FNA and SIBN, which typically issue full-year guidance with Q4 earnings.
Procept BioRobotics reported strong revenue growth of 66% in the third quarter, largely attributed to the company's Hydros units. The company also initiated a public offering of common stock valued at $175 million. Analyst firms such as Morgan Stanley (NYSE:MS) and Jefferies have provided their analysis on Procept BioRobotics, with Morgan Stanley initiating coverage with an Overweight rating.
These are recent developments, providing investors with an overview of the financial health and strategic movements of these companies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.